Multiple Alliances Expand Brii’s Commitment To Anti-Infectives
New Venture AN2 Among Partners
China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.
You may also be interested in...
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.